[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336227-105":59,"doc-detail-336227-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","targeted-therapies-prime-oncogene-driven-lung-cancers-for-macrophage-mediated-destruction-research-article","Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction - Research article","","Macrophage immune checkpoint inhibitors, including anti-CD47 antibodies, are being tested for solid and hematologic malignancies, but optimal therapeutic strategies remain unclear. To address this, an unbiased high-throughput screening platform was used to find drugs that make lung cancer cells more vulnerable to macrophage attack. The study shows synergy between genotype-directed therapies and anti-CD47, producing robust phagocytosis and eliminating persister cells in vitro while maximizing antitumor responses in vivo across multiple RTK/MAPK pathway alterations. Mechanistically, enhanced sensitivity correlates with downregulation of β2-microglobulin and CD73.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeted-therapies-prime-oncogene-driven-lung-cancers-for-macrophage-mediated-destruction-research-article/336227/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeted-therapies-prime-oncogene-driven-lung-cancers-for-macrophage-mediated-destruction-research-article/336227.png","ImageObject",300,407,{"name":92,"@type":93},"Emma Wilson","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What therapeutic combination does the study evaluate for lung cancer treatment?","Question",{"text":112,"@type":113},"The study evaluates synergy between genotype-directed targeted therapies and anti-CD47 antibodies to enhance macrophage-mediated destruction of lung cancer cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was drug sensitivity to macrophage attack identified?",{"text":117,"@type":113},"An unbiased high-throughput screening platform was developed to find drugs that render lung cancer cells more vulnerable to macrophage attack.",{"name":119,"@type":110,"acceptedAnswer":120},"Which molecular changes are linked to increased sensitivity to macrophage attack?",{"text":121,"@type":113},"Downregulation of β2-microglobulin and CD73 is reported as contributing to enhanced sensitivity of lung cancer cells to macrophage attack.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336227,1790977064,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","The Journal of Clinical Investigation RESEAR CH ARTICLE  \nTargeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction  \nKyle Vaccaro,1 Juliet Allen,1 Troy W. Whitfield,1 Asaf Maoz,1,2 Sarah Reeves,3 José Velarde,1 Dian Yang,1 Anna Meglan,1 Juliano Ribeiro,1 Jasmine Blandin,1 Nicole Phan,3 George W. Bell,1 Aaron N. Hata,3,4 and Kipp Weiskopf1,2,5  \n1Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA. 2Dana-Farber Cancer Institute, Boston, Massachusetts, USA. 3Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA. 4Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. 5Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.  \nMacrophage immune checkpoint inhibitors, such as anti-CD47 antibodies, show promise in clinical trials for solid and hematologic malignancies. However, the best strategies to use these therapies remain unknown, and ongoing studies suggest they may be most effective when used in combination with other anticancer agents. Here, we developed an unbiased, highthroughput screening platform to identify drugs that render lung cancer cells more vulnerable to macrophage attack, and we found that therapeutic synergy exists between genotype-directed therapies and anti-CD47 antibodies. In validation studies, we found that the combination of genotype-directed therapies and CD47 blockade elicited robust phagocytosis and eliminated persister cells in vitro and maximized antitumor responses in vivo. Importantly, these findings broadly applied to lung cancers with various RTK/MAPK pathway alterations — including EGFR mutations, ALK fusions, or KRASG12C mutations. We observed downregulation of β2-microglobulin and CD73 as molecular mechanisms contributing to enhanced sensitivity to macrophage attack. Our findings demonstrate that dual inhibition ofthe RTK/MAPK pathway and the CD47/SIRPa axis is a promising immunotherapeutic strategy. Our study provides strong rationale for testing this therapeutic combination in patients with lung cancers bearing driver mutations.  \nIntroduction  \nMany cancers arise from a single mutation in a proto-oncogene that drives tumor growth. These cancers are often treated with genotype-directed “targeted therapies,” small-molecule inhibi-  \nRelated Commentary: [https://doi.org/10.1172/JCI180512](https://doi.org/10.1172/JCI180512)  \nAuthorship note: KV and JA contributed equally to this work and are co–first authors. Conflict of interest: KV is a former employee and equity owner of DEM Biopharma.  \nDY is a cofounder, scientific advisory board member, and equity holder of DEM Biopharma. NP is a current employee of Bristol-Myers Squibb. ANH has received research support from Amgen, Blueprint Medicines, BridgeBio, Bristol-Myers Squibb, C4 Therapeutics, Eli Lilly, Novartis, Nuvalent, Pfizer, Roche/Genentech, Scorpion Therapeutics and has served as a compensated consultant for Nuvalent, Oncovalent, Tolremo Therapeutics, Engine Biosciences, and TigaTx. KW declares patents and royalties, including patents and royalties (issued US patent nos. 9,771,428, 9,945,870, 9,944,911, 10,064,925, 10,081,680, 10,184,004, 10,316,094, 10,358,472, 10,406,179, 10,723,803, 10,781,256, 10,889,649, 10,894,831, 11,046,763, 11,154,600, 11,208,481, 11,230,607, 11,419,897, 11,459,388, 11,608,377, 11,780,931), with Stanford University, Whitehead Institute, and Gilead Sciences; is a cofounder, scientific advisory board member, and equity holder of ALX Oncology and DEM Biopharma; and is a scientific advisor for Carisma Therapeutics. KW is a cofounder, scientific advisory board member, and equity holder in Solu Therapeutics and reports stock ownership in Ginkgo Bioworks. KW, ANH, KV, JA, DY, and A Maoz have filed US patent applications (PCT/ US2023/014838, PCT/US2023/027749, PCT/US2023/014836, PCT/US2023/027792, PCT/US2023/034666, PCT/US2023/012","cbCaijb6f8aUPxa6","https://ap.wps.com/l/cbCaijb6f8aUPxa6","pdf",6465190,15,"English","# Introduction\n## Rationale for combining targeted therapies with immune checkpoint inhibition\n## Focus on macrophage-directed therapies and the CD47/SIRPα axis\n## High-throughput screening to identify macrophage-sensitizing drugs\n## Validation of synergy between genotype-directed therapy and anti-CD47\n## Molecular mechanisms underlying macrophage sensitivity\n## Implications for treating driver-mutation lung cancers","[{\"question\":\"What therapeutic combination does the study evaluate for lung cancer treatment?\",\"answer\":\"The study evaluates synergy between genotype-directed targeted therapies and anti-CD47 antibodies to enhance macrophage-mediated destruction of lung cancer cells.\"},{\"question\":\"How was drug sensitivity to macrophage attack identified?\",\"answer\":\"An unbiased high-throughput screening platform was developed to find drugs that render lung cancer cells more vulnerable to macrophage attack.\"},{\"question\":\"Which molecular changes are linked to increased sensitivity to macrophage attack?\",\"answer\":\"Downregulation of β2-microglobulin and CD73 is reported as contributing to enhanced sensitivity of lung cancer cells to macrophage attack.\"}]","Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction - Research article | PDF",1790014197,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1424be2494a6c462b4912c092c7b1c8b.webp",983,1315,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/73d8ae93f30c345b79bc4cf97924f633.webp",982,1314,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/941fb73ce6529cd3d486a14fd83c901d.webp",981,1312,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0af86dd8e27da25cf7983abe3118d60.webp",980,1311]